TerSera Therapeutics LLC today announced that it has completed the previously announced sale of its Infusion Specialty Therapies Business Unit (IST), including two specialty medications, Prialt(R) ...
Camp4 Therapeutics FY25 GAAP EPS missed expectations, but ended the year with a robust cash position. Check out why CAMP ...
Good morning, everybody, and thank you for joining us for the 46th Annual TD Cowen Healthcare Conference. I'm Yaron Werber from the biotech team, and it's really a great pleasure to moderate the next ...
Eli Lilly LLY-1.01%decrease; red down pointing triangle received approval from the Food and Drug Administration for a label expansion of its weight-loss drug Zepbound, adding a new monthly delivery ...
Feb 23 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it received the U.S. Food and Drug Administration's approval to launch a four-dose KwikPen for its weight-loss drug Zepbound, ...
Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some ...
About a month after securing a label expansion from the FDA for multidose pen versions of Zepbound, Eli Lilly is making the KwikPens available to self-paying users of its direct-to-consumer drug sales ...
A one-month, four-dose pen could reduce injector component consumption and assembly cycles, addressing a key constraint that has limited GLP-1 category supply reliability. Consolidation of doses may ...
Feb 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Tuesday the European Commission has approved a higher dose of its popular obesity drug Wegovy, providing patients and doctors with an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results